14/11/2011 - 15:43

pSivida plunges on FDA knock-back

14/11/2011 - 15:43

Bookmark

Save articles for future reference.

Stocks in Perth-based biotech pSivida have halved in value after the United States Food and Drug Administration declined to approve its treatment for back-of-the-eye problems associated with diabetes. At close of trade today pSivida’s stock had lost 48.7 per cent, to trade at $2.10.

To read our articles you will need to either login or subscribe.

STANDING BY BUSINESS. TRUSTED BY BUSINESS.

Subscription Options